Abstract
The trials presented in this section deal with four major issues in the adjuvant treatment of breast cancer: the optimal duration of therapy, treatment intensity, implications regarding drug schedule, and the role of combining tamoxifen with chemotherapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Holland JF (1983) Breaking the cure barrier. J Clin Oncol 1: 75–90
Muss HB, White DR, Cooper R, Richards II F, Spurr CL (1977) Combination chemotherapy in advanced breast cancer. Arch Intern Med 137: 1711–1714
Tormey DC, Gelman R, Band PR, Sears M, Rosenthal SN, DeWys W, Perlia C, Rice MA (1982) Comparison of induction chemotherapies for metastatic breast cancer: an Eastern Cooperative Oncology Group trial. Cancer 50: 1235–1244
Tormey DC, Gelman R, Falkson G (1983) Prospective evaluation of rotating chemotherapy in advanced breast cancer: An Eastern Cooperative Oncology Group trial. Am J Clin Oncol 6: 1–8
Engelsman E, Mouridsen HT, Palshof T, Sylvester R (1981) CMF vs CMF plus tamoxifen in advanced breast cancer in postmenopausal women. An EORTC study. Rev Endocrine Related Cancer [Suppl] 9: 427–438
Tormey DC, Falkson G, Crowley J, Falkson HC, Voelkel J, Davis TE (1982) Dibromodulcitol and adriamycin ± tamoxifen in advanced breast cancer. Cancer Clin Trials 5: 33–39
Canellos GP, Pocock SJ, Taylor SG III, Sears ME, Klaasen DJ, Band PR (1976) Combination chemotherapy for metastatic breast carcinoma. Prospective comparison of multiple drug therapy with L-phenylalanine mustard. Cancer 38: 1882–1886
DeLena M, Brambilla C, Morbito A, Bonadonna G (1975) Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer. Cancer 35: 1108–1115
Tormey DC, Weinberg VE, Leone LA, Glidewell OJ, Perloff M, Kennedy BJ, Cortes E, Silver RT, Weiss RB, Aisner J, Holland JF (to be published) A comparison of intermittent vs continuous and of adriamycin vs methotrexate 5-drug chemotherapy for advanced breast cancer — a cancer and leukemia group B study. Am J Clin Oncol
Hoogstraten B, George SL, Samal B, Rivkin SE, Costanzi JJ, Bonnet JD, Thigpen T, Braine H (1976) Combination chemotherapy and adriamycin in patients with advanced breast cancer. Cancer 38: 13–20
Osborne CK, Blodt DH, Clark GM, Trent JM (1983) Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. Cancer Res 43: 3583–3585
Jordan VC, Dix CJ, Allen KE (1979) The effectiveness of long-term tamoxifen treatment in a laboratory model for adjuvant hormone therapy of breast cancer. In: Jones SE, Salmon SE (eds) Adjuvant therapy of cancer II. Grune and Stratton, New York, pp 19–26
Tormey DC, Jordan VC (to be published) Adjuvant chemotherapy and chemohormonal therapy in postoperative N+ patients. In: Breast cancer — Therapeutic modalities, current and future
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Tormey, D.C. (1984). Review: Experience of Randomized Trials Without Surgical Controls. In: Senn, HJ. (eds) Adjuvant Chemotherapy of Breast Cancer. Recent Results in Cancer Research, vol 96. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-82357-2_23
Download citation
DOI: https://doi.org/10.1007/978-3-642-82357-2_23
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-82359-6
Online ISBN: 978-3-642-82357-2
eBook Packages: Springer Book Archive